Funding vs FDA Actions
Side-by-side coverage analysis for Funding and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Funding
Biotech venture funding, grants
- Stories
- 20
- Avg Impact
- 6.3/10
- Dominant Tone
- Bullish
- Latest
- 4d ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 20
- Avg Impact
- 7/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
Recent Headlines
Funding
- Biotech Portfolio in Limbo as Court Removes $1.5B Fund Chief
- Biotech VC hits $9.1B in H1 but preclinical funding gap deepens
- Less Than 1% Funding for Sarcoma: Biotech Opportunity in Rare Cancer R&D
- 38 Cases, 60%+ Hospitalized: Can Biotech Prevent the Next Legionnaires' Outbreak?
- Biotech Eyes $1.4B Ebola Funds as US War Bill Tops $87B
- Info Edge's Biotech Bets: Rs 455 Cr Deeptech Fund Includes String Bio
- 40%+ revenue from small biotech gives Charles River an edge in funding rebound
- Biotech & Health among 13 Sectors as 500+ Investors Eye Indian Deep-Tech
- $12B Bet on AGI Drug Design: Bezos’s Prometheus Targets Biotech Manufacturing
- Alto Neuroscience Secures $120M to Advance Precision Psychiatry Pipeline
FDA Actions
- Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
- Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
- Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
- Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
- Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
- HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
- AIIMS Recruits 460+ Researchers, Supercharging India’s Biomedical Pipeline
- First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status
- Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions
- $6.5B Fraud Sweep Nabs Genetic Testing Scams: Biotech’s Compliance Wake-Up Call